Literature DB >> 27458314

Oral Health and Hospital-Acquired Pneumonia in Elderly Patients: A Review of the Literature.

Lauren A Kanzigg, Lynne Hunt.   

Abstract

PURPOSE: The U.S. spends an average of $6.5 billion each year to treat patients who suffer from pneumonia. Pneumonia currently has the highest morbidity and mortality rates of all nosocomial infections, is hypothesized to account for 15% of all hospital-acquired illnesses and is responsible for 13 to 48% of all nursing home-associated illnesses. For years, researchers have tried to develop methods to prevent pneumonia because of its detrimental effects on the body, but only in the last decade have they been able to uncover possible methods to do so. Inadequate oral hygiene care is one of the ways that elderly patients contract hospital-acquired pneumonia (HAP). Proper oral disease prevention could possibly be considered the standard of care in long-term stay facilities to reduce and prevent elderly patients from contracting HAP. The purpose of this literature review is to explore the relationship between oral health care practices and HAP.
Copyright © 2016 The American Dental Hygienists’ Association.

Entities:  

Keywords:  dental hygiene educators; elderly patients; periodontal disease; pneumonia

Mesh:

Year:  2016        PMID: 27458314

Source DB:  PubMed          Journal:  J Dent Hyg        ISSN: 1043-254X


  2 in total

1.  A retrospective study on risk factors and disease burden for hospital-acquired pneumonia caused by multi-drug-resistant bacteria in patients with intracranial cerebral hemorrhage.

Authors:  Haojun Yang; Yishu Fan; Mengqi Zhang; Weiping Liu; Chunhui Li
Journal:  Neurol Sci       Date:  2021-11-08       Impact factor: 3.307

2.  The impact of individual lifestyle and status on the acquisition of COVID-19: A case-Control study.

Authors:  Chang Gao; Zhi Zhao; Fengyuan Li; Jia-Lin Liu; Hongyang Xu; Yuanying Zeng; Ling Yang; Jiahao Chen; Xiaoting Lu; Can Wang; Qiang Guo
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.